Sabinsa granted new patents for ForsLean to make energy balance claims
Sabinsa Corp. has been awarded new patents for its branded Coleus forskohlii extract, ForsLean ingredient.
Photo © iStockphoto.com
Sabinsa Corp. (East Windsor, NJ) has been awarded new patents for its branded Coleus forskohlii extract, ForsLean ingredient. Japenese Patent Number 6472453, US Patent Number 10085963, and Australian Patent Number 2015351423 are entitled “Process and compositions for achieving mammalian energy balance,” and define a method of achieving optimal mammalian energy using Forskolin, the active compound in ForsLean.
The molecular mechanism outlined in the patents is the conversion of fat into heat, a novel concept called energy balance. Forskolin aids in the conversion of white fat tissue, which stores energy in the form of triglycerides, to brown fat tissue, which dissipates energy in the form of heat. This is a process crucial for fat utilization and effective energy utilization, or balance, says Sabinsa.
CRN NY State lawsuit update: Dispatch from SupplySide East 2024
April 18th 2024CRN's Steve Mister updates Nutritional Outlook about its ongoing litigation against NY State. The organization sued the state to prevent the enforcement of law that bans sale of weight management supplements to minors.
